Upside – $ALEC +58% (global AL050 license brings $100M upfront, up to $1.17B in milestones and extends the cash runway into 2029) – $PCVX +55% (VAX-31 OPUS-1 pivotal Phase 3 trial met all prespecified primary endpoints with a safety profile comparable to existing vaccines) – $PTC +36% (agrees to a $205-a-share all-cash takeover valuing its …
Read in context ›XP Stock (XP)
Track XP stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
XP
XP
financial
At close
$32.22
â–² +2.01 (+6.65%)
Oct 9, 4:00 PM ET
After-hours
$32.30
â–² +0.08 (+0.25%)
Oct 9, 7:55 PM ET
Market Cap
$15.62B
P/E Ratio
15.5x
1Y Return
+102.77%
EPS (TTM)
$1.94
Read the latest TheStreet Pro articles mentioning XP, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
0 articlesNo articles mentioning XP yet.
Daily Diary Mentions
1 mentionUpside, Downside Movers in the Morning